• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Skip to investors navigation
Insmed

Insmed

Powered by Purpose

LinkedIn Twitter Contact Us Job Opportunities

  • Culture
    • Our Culture
      • Mission & Vision
      • Careers
      • Responsibility
        • Inclusion at Insmed
        • Grants & Funding
        • Global Healthcare Compliance

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients
    • Our Patients
      • Disease Areas
      • Resources
      • Patient Access

    Current Clinical Trials

    You may be eligible for one of our clinical trials.

    See if you may qualify

  • Science
    • Our Science
      • Our Pillars
        • ARIKAYCE®
        • Brensocatib
        • TPIP
        • Early-Stage Research
      • Pipeline
      • Clinical Trials
      • Investigator-Initiated Research

    Our Research Team

    Working together to develop new medicines and technologies that have the potential to transform patients’ lives.

    Learn More

  • About
    • About Insmed
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs
Home / Investors/ News Releases

News Releases

Month Year
Su Mo Tu We Th Fr Sa
Month Year
Su Mo Tu We Th Fr Sa
Email Alerts
Advanced Search
  
Asset Types
           
 Basic Search
  • May 29, 2003
    Insmed to Present Positive Cancer Data to ASCO
    Insmed to Present Positive Cancer Data to ASCO
  • May 16, 2003
    Insmed Incorporated to Present at Techvest European Healthcare Conference
    Insmed Incorporated to Present at Techvest European Healthcare Conference
  • May 12, 2003
    Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
    Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
  • May 2, 2003
    Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
    Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
  • Apr 25, 2003
    Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
    Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
  • Apr 11, 2003
    Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
    Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
  • Apr 8, 2003
    Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
    Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
  • Apr 8, 2003
    Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
    Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
  • Apr 7, 2003
    Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
    Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
  • Apr 4, 2003
    Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
    Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
  • Apr 2, 2003
    Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
    Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
  • Apr 1, 2003
    Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
    Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
  • Mar 28, 2003
    Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
    Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
  • Feb 3, 2003
    Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
    Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
  • Jan 29, 2003
    Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
    Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
  • Jan 28, 2003
    Insmed Incorporated to Webcast Fourth Quarter Earnings Conference Call; Tuesday, February 4, at 8:00 a.m. ET - 7:00 a.m. CT
    Insmed Incorporated to Webcast Fourth Quarter Earnings Conference Call; Tuesday, February 4, at 8:00 a.m. ET - 7:00 a.m. CT
  • Jan 27, 2003
    Insmed Incorporated Appeals Delisting Notification From Nasdaq
    Insmed Incorporated Appeals Delisting Notification From Nasdaq
  • Jan 7, 2003
    Insmed Incorporated Announces Positive Preclinical Oncology Data With rhIGFBP-3
    Insmed Incorporated Announces Positive Preclinical Oncology Data With rhIGFBP-3
  • Dec 16, 2002
    Insmed Announces Senior Management Changes
    Insmed Announces Senior Management Changes
  • Nov 4, 2002
    Insmed Presents IGFBP-3 Anti-Cancer Data at the International Symposium on the Functional Role of IGFBP's
    Insmed Presents IGFBP-3 Anti-Cancer Data at the International Symposium on the Functional Role of IGFBP's
  • Oct 31, 2002
    Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
    Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
  • Oct 30, 2002
    Insmed Incorporated Reports Third Quarter Results
    Insmed Incorporated Reports Third Quarter Results
  • Oct 7, 2002
    Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine
    Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine
  • Sep 23, 2002
    Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources
    Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources
  • Sep 10, 2002
    Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -
    Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -
Show 5102550100 per page
  • «
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • »
Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download

Primary Sidebar

Investor Menu

  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

Investor Menu

Footer

Insmed
LinkedIn Twitter

Contact Us

Job Opportunities

  • Our Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Our Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Our Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
  • Events & Presentations
  • Stock Information
  • News Releases
  • SEC Filings
  • Annual Reports
  • Analyst Coverage
  • Corporate Governance
  • Email Alerts
  • Investor FAQs

© 2023 Insmed Incorporated. All Rights Reserved. Terms of Use Privacy Policy

Culture
Patients
Science
logo
  • Culture
    • Mission & Vision
    • Careers
    • Responsibility
      • Inclusion at Insmed
      • Grants & Funding
      • Global Healthcare Compliance
  • Patients
    • Disease Areas
    • Resources
    • Patient Access
  • Science
    • Our Pillars
      • ARIKAYCE®
      • Brensocatib
      • TPIP
      • Early-Stage Research
    • Pipeline
    • Clinical Trials
    • Investigator-Initiated Research
  • About
    • Management Team
    • Board of Directors
    • Partnerships
  • Investors
    • Investors
    • Events & Presentations
    • Stock Information
    • News Releases
    • SEC Filings
    • Annual Reports
    • Analyst Coverage
    • Corporate Governance
    • Email Alerts
    • Investor FAQs

LinkedIn Twitter

Contact Us Job Opportunities

© 2023 Insmed Incorporated.
All Rights Reserved.

Terms of Use Privacy Policy